Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 9, Stifel increased its price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) from $15 to $24 while keeping a Buy rating on the stock. The firm pointed to recent progress in PRMT5 inhibitors and RAS(ON) combinations, which the firm believes lowers the risk for the company’s first-line pancreatic ductal adenocarcinoma opportunity. Stifel also included risk-adjusted first-line pancreatic duct ...